GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Cash, Cash Equivalents, Marketable Securities

Knight Therapeutics (TSX:GUD) Cash, Cash Equivalents, Marketable Securities : C$180.9 Mil (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Cash, Cash Equivalents, Marketable Securities?

Knight Therapeutics's quarterly cash, cash equivalents, marketable securities increased from Sep. 2024 (C$172.32 Mil) to Dec. 2024 (C$172.84 Mil) and increased from Dec. 2024 (C$172.84 Mil) to Mar. 2025 (C$180.86 Mil).

Knight Therapeutics's annual cash, cash equivalents, marketable securities declined from Dec. 2022 (C$191.22 Mil) to Dec. 2023 (C$170.17 Mil) but then increased from Dec. 2023 (C$170.17 Mil) to Dec. 2024 (C$172.84 Mil).


Knight Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Knight Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

Knight Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 411.34 162.99 191.22 170.17 172.84

Knight Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 192.25 157.47 172.32 172.84 180.86

Knight Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Knight Therapeutics  (TSX:GUD) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Knight Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.
Executives
Sime Armoyan 10% Security Holder
Samira Sakhia Director, Senior Officer
Amal Khouri Senior Officer
Jonathan Ross Goodman Director, Director or Senior Officer of 10% Security Holder
Robert Nathaniel Lande Director
Long Zone Holdings Inc. 10% Security Holder
Janice Jean Murray Director
Nicolas Sujoy Director
Arvind Utchanah Senior Officer
Michael Joseph Tremblay Director
James Gale Director
Michael Dehn Director, Senior Officer
Andrew Moor Senior Officer
Patrick Mcclymont Senior Officer
Kevin Drew Nabholz Director

Knight Therapeutics Headlines

No Headlines